IPP Bureau
Glenmark initiates multi-country Phase 3 clinical trial for Envafolimab in resectable Stage III NSCLC
By IPP Bureau - September 06, 2025
The company has received approval from DCGI to begin patient enrolment and dosing in the country
Poly Medicure to acquire 90% stake in PendraCare Group for € 18.3 million
By IPP Bureau - September 06, 2025
PendraCare Group develops, manufactures and sells innovative cardiology catheter solutions and provides design, development and manufacturing services to other global OEM’s
Jagsonpal Pharmaceuticals appoints Amrut Medhekar as Chief Operating Officer
By IPP Bureau - September 06, 2025
Indegene opens new center in Pune
By IPP Bureau - September 06, 2025
Zydus Lifesciences gets 4 USFDA observations for Jarod Injectable facility
By IPP Bureau - September 06, 2025
Zydus will work closely with the USFDA to address and resolve the observations in an expeditious manner
iPHEX 2025: Piyush Goyal calls for deeper global collaborations to strengthen healthcare systems worldwide
By IPP Bureau - September 05, 2025
Goyal reaffirmed the government’s commitment to facilitating market access, reducing trade barriers, and ensuring that Indian exporters remain globally competitive
Granules India and NIPER S.A.S Nagar launch CoE for sustainable pharma innovation
By IPP Bureau - September 05, 2025
It will focus on interface between API and formulation manufacturing, reducing carbon footprint in formulation production, creating intellectual property, training next-generation scientists, and setting new industry benchmarks
DPIIT signs MoU with Pfizer to strengthen India’s healthcare innovation ecosystem
By IPP Bureau - September 05, 2025
Under the partnership, the Pfizer INDovation program will empower DPIIT-recognized startups with grants of up to Rs. 60 lakhs each, along with a tailored 18-month incubation program delivered by Social Alpha
MedTech Expo 2025: ICMR licenses nine technologies to 17 industry partners
By IPP Bureau - September 05, 2025
These licenses are given in areas of infectious disease diagnostics, immunodiagnostics, and vaccine development
Zydus and Synthon ink licensing and supply agreement for Ozanimod Capsules for US market
By IPP Bureau - September 05, 2025
Under the terms of this agreement, Synthon will be responsible for obtaining final regulatory approval for its Ozanimod Capsules product
Edwards Lifesciences launches next-gen transcatheter heart valve in India
By IPP Bureau - September 05, 2025
Edwards’ latest-generation balloon-expandable transcatheter heart valve incorporates a proprietary calcification-resistant tissue technology
FDA completes inspection at Biocon Biologics' facility in Bengaluru
By IPP Bureau - September 05, 2025
The U.S. FDA issued a Form 483 with five observations
AstraZeneca’s Baxdrostat proves effective in in Phase III trial for hard-to-control hypertension
By IPP Bureau - September 05, 2025
The medicine was well tolerated, with no unexpected safety issue
CapVest to acquire majority stake in STADA
By IPP Bureau - September 05, 2025
Bain Capital and Cinven will each retain a minority stake, reflecting their ongoing confidence in STADA’s future growth
Resolution Therapeutics doses first patient in phase I/II Emerald study of RTX001 for end-stage liver disease
By IPP Bureau - September 05, 2025
RTX001 represents a groundbreaking advance in the treatment of end-stage liver disease, offering new hope for patients with limited options
